Japan Sees Biggest Jump on Record in Individual Shareholdings
That's an increase of 9.14 million from the previous year, according to an annual share ownership survey by Japan Exchange Group Inc., or JPX, which runs the country's major bourses. It's also the biggest jump in the number of individual holdings since it started compiling the data in 1949.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
Evercore ISI Maintains a Buy on Enovis Corporation (ENOV) With a $46 PT
Enovis Corporation (NYSE:ENOV) is one of the best undervalued medical device stocks to buy now. In a report released on July 8, Vijay Kumar from Evercore ISI maintained a Buy rating on Enovis Corporation (NYSE:ENOV) and set a price target of $46.00. A patient recieving cold therapy treatment using the company's products. The company reported continued commercial momentum in fiscal Q1 2025 results, with net sales for the quarter reaching $559 million and reported an 8% growth on a reported basis and 9% rise on a comparable basis from the same quarter last year. Reconstructive sales for the quarter rose 11% year-over-year on a reported basis. Enovis Corporation's (NYSE:ENOV) fiscal Q1 2025 results show a rebound in growth in Recon, net sales for which grew 11% on a reported and comparable basis. The company also showed accelerating momentum in new product introductions and continued execution in P&R, reflecting a 5% growth on a reported basis and 7% on a comparable growth basis. Enovis Corporation (NYSE:ENOV) is a medical technology growth company that develops clinically differentiated solutions to transform workflows and generate better patient outcomes. The company operates through the Prevention & Recovery and Reconstructive segments. While we acknowledge the potential of ENOV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
10 minutes ago
- Yahoo
ZimVie (ZIMV) Announces the Launch of its RealGUIDE Software Suite and Implant Concierge Service in Japan
ZimVie Inc. (NASDAQ:ZIMV) is one of the best undervalued medical device stocks to buy now. On June 5, ZimVie Inc. (NASDAQ:ZIMV) announced the launch of its RealGUIDE Software Suite and Implant Concierge service in Japan. A medical professional working on a dental implant in an operating room. The launch of the service in the Japenese market provides dentists expanded access to a digital dental implant ecosystem that extends from implant planning to placement and offers vertically integrated, end-to-end solutions. Management reported that the dental implant market opportunity is significant in Japan, and the country is ZimVie Inc.'s (NASDAQ:ZIMV) largest market in the APAC region. RealGUIDE software is the first complete cloud-based solution of its kind, and offers dentists all they need for precise implant planning, restorative design, and surgical guides to deliver time, workflow, and cost efficiencies. Implant Concierge is a virtual outsourcing service that aims to simplify and streamline guided surgery and implant treatment planning. ZimVie Inc. (NASDAQ:ZIMV) manufactures, designs, and distributes medical devices and surgical instruments. The company's operations are divided into the Spine Products and Dental Products segments. While we acknowledge the potential of ZIMV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
10 minutes ago
- Yahoo
Piper sees H20 ban hurting Nvidia sales by $8B in July quarter
Piper Sandler keeps an Overweight rating on Nvidia (NVDA) after the company said it expects to be granted licenses to resume H20 chip sales to China. During the April quarter, the company posted $4.6B in sales for H20 and left an additional $2.5B on the table due to the ban, the analyst tells investors in a research note. Piper says the estimated impact from the ban in the July quarter was around $8B in sales. It suspects strong demand for these chips would have continued should the ban not been in place. The merchant artificial intelligence companies alongside Nvidia, namely Micron (MU) and AMD (AMD), would benefit from the lifting of this ban, contends Piper. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on NVDA: Disclaimer & DisclosureReport an Issue Nvidia price target raised to $195 from $160 at DZ Bank Notable open interest changes for July 15th Video: Nvidia, AMD jump as shipments to China expected to resume Eaton, Nvidia collaborate on power infrastructure in artificial intelligence Nvidia price target raised to $235 from $205 at Melius Research Sign in to access your portfolio
